CN110054666A - A kind of polypeptide and its application for inhibiting cell PD-L1 to express - Google Patents
A kind of polypeptide and its application for inhibiting cell PD-L1 to express Download PDFInfo
- Publication number
- CN110054666A CN110054666A CN201910185978.2A CN201910185978A CN110054666A CN 110054666 A CN110054666 A CN 110054666A CN 201910185978 A CN201910185978 A CN 201910185978A CN 110054666 A CN110054666 A CN 110054666A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- cell
- seq
- expression
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Abstract
The invention discloses a kind of polypeptide for inhibiting cell PD-L1 to express and its applications, and the amino acid sequence of the polypeptide is as shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3；Cell experiment is as the result is shown, the up-regulation of cell PD-L1 transcriptional level and protein level that the polypeptide can inhibit IFN-γ to induce, show that polypeptide of the invention inhibits the drug of cell PD-L1 transcription and protein expression in preparation, and there is biggish application prospect in the drug that preparation blocks PD-1/PD-L1 interaction, it is expected to substitute current PD-L1 immunization therapy monoclonal antibody.
Description
Technical field
The present invention relates to field of biomedicine technology, more particularly, to a kind of more for inhibiting cell PD-L1 to express
Peptide and its application.
Background technique
Immunotherapy of tumors is the therapeutic modality for referring to stimulation body and generating anti-tumor immune response, including following several
Aspect: specific inhibition antibody target immunologic test point, such as anti-PD-L1, anti-PD1, anti-CTLA4；Engineered ex vivo or
The T cell of person's activation, such as CAR-T, TCR-T；Adjust the cell factor of immunization, such as IL-2；Anti-tumor vaccine etc..Wherein,
The monoclonal antibody of targeting immunologic test point PD1 and PD-L1 shows good treatment in the clinical application of kinds of tumors
Effect.PD-1 is the co-suppression acceptor molecule expressed on immunocyte surface, PD-L1 (CD274, B7H1) and PD-L2 (CD273,
B7-DC) it is its two ligands.Since PD-L1 ratio PD-L2 is expressed more extensively in tumor tissues, and evidence suggests swell
The expression of oncocyte PD-L1 has direct effect to the immunosupress in tumor microenvironment, blocks PD-1/PD-L1 mutual
Effect can reactivate the T cell in tumor microenvironment, and inhibition even is eliminated tumour, so, PD-1/PD-L1 interaction
It is the major target class of immunotherapy of tumors.
Block the immunization therapy of PD-1/PD-L1 interaction significant in efficacy in view of targeting, by the end of the year 2018, global model
Carrying out in enclosing there are also more than 2,000 clinical tests for this target spot, is covering nearly all common tumor type.
Currently, China has been approved by the monoclonal antibody medicine for having listed multiple targeting PD-1, also energetically opened for the monoclonal antibody medicine of PD-L1
It opens up in clinical test.The immunotherapy of tumors of PD-1/PD-L1 interaction is blocked to show fine prospect, but it is this
Treatment method also faces a series of problem of sternnesses, has seriously affected the therapeutic effect of immunotherapy of tumors, while also restricting
Its beneficiaries and its be widely used.These problems include that low response rate, drug resistance, medical expense be high, autoimmunity pair
Effect etc..Cause these problems one reason for this is that the monoclonal antibody itself that immunization therapy uses.Due to monoclonal antibody medicine identification
Epitope is single, and it is different to the response rate of monoclonal antibody to may cause different tumours, Different Individual.Meanwhile monoclonal antibody medicine is also possible to
Cause immunological rejection, generates anti-antibody, cause drug resistance.In addition, antibody drug produces, save, the particularity of the links such as transport,
Also result in its higher cost.Moreover, monoclonal antibody medicine is unable to specific enrichment in tumor region at present, so increasing immune control
Treat the generation of side effect.
Peptide targeted small molecule drugs at low cost, molecular weight is small, good biocompatibility, penetrability are strong, without immunogene
Property and have faster blood clearance rate and prepare the features such as simple, cancer target administration, in terms of show
Very strong superiority out, or even show the trend of substitution antibody class diagnosis and treatment reagent.But currently, there has been no utilize specific target
Inhibit report of the PD-L1 expression to block PD-1/PD-L1 to interact to polypeptide.
Summary of the invention
The technical problem to be solved by the present invention is to overcome above-mentioned the deficiencies in the prior art, provide a kind of inhibition cell PD-L1
Expression, and the polypeptide of current PD-L1 immunization therapy monoclonal antibody may be substituted.The cell PD- that the polypeptide can inhibit IFN-γ to induce
The up-regulation of L1 transcriptional level and protein level blocks PD-1/PD-L1 interaction.
The first purpose of the invention is to provide a kind of polypeptides for inhibiting cell PD-L1 to express.
A second object of the present invention is to provide the applications of the target polypeptide.
Above-mentioned purpose of the invention is to give realization by the following technical programs:
A kind of polypeptide inhibiting cell PD-L1 expression, the amino acid sequence of the polypeptide are as shown below:
IPGLIWINKEEMIFQIPWKHAA(SEQ ID NO.1)。
The polypeptide of the present invention for inhibiting cell PD-L1 expression can also be connect with various target polypeptides, thus the SEQ made
Polypeptide described in ID NO.1 has better targeting, cell permeability.
Specifically, the present invention also provides a kind of target polypeptide Tat- containing polypeptide sequence described in above-mentioned SEQ ID NO.1
The sequence of 2142 fused polypeptides, the fused polypeptide is as follows: YGRKKRRQRRRGGGIPGLIWINKEEMIFQIPWKHAA
(SEQ ID NO.2)；The Tat-2142 fused polypeptide passes through three glycine of N-terminal for selectively targeted sequence SEQ ID
NO.1 is coupled with Tat polypeptide sequence.After coupling, selectively targeted sequence SEQ ID NO.1 can be in cell penetrating peptide Tat polypeptide
Across cell membrane under guidance, into cell.
And another contain polypeptide sequence described in above-mentioned SEQ ID NO.1 target polypeptide 2142-iRGD fusion it is more
The sequence of peptide, the fused polypeptide is as follows: IPGLIWINKEEMIFQIPWKHAAGGGCRGDKGPDC (SEQ ID
NO.3)；The 2142-iRGD fused polypeptide sequence passes through two cysteine cyclization of its C-terminal.The 2142-iRGD fusion
Selectively targeted sequence SEQ ID NO.1 and iRGD polypeptide sequence is coupled by polypeptide by three glycine.By that will swell
Tumor target polypeptide iRGD is connected with the protein sequence of selectively targeted sequence SEQ ID NO.1, can preferably play SEQ ID
The neoplasm targeted therapy of polypeptide described in NO.1 acts on.
The present invention passes through cell experiment it was demonstrated that the cell that polypeptide shown in SEQ ID NO.2 can inhibit IFN-γ to induce
The up-regulation of PD-L1 transcriptional level and protein level shows that polypeptide of the invention can be used for preparing and inhibits cell PD-L1 transcription and egg
The drug of white expression.
Since PD-L1 has up-regulated expression in kinds of tumor cells, it can inhibit T thin in conjunction with the PD-1 in T cell
Born of the same parents' proliferation and activation, make T cell be in inactivated state, finally induce immunologic escape.By inhibiting cell PD-L1 transcription and albumen
Expression can block PD-1/PD-L1 to interact, and tumour cell and T cell is blocked to combine, raise T cell growth and
Proliferation enhances identification of the T cell to tumour cell, activates its attack and killing ability, passes through the immune function for transferring human body itself
It is able to achieve antitumor action.Target polypeptide of the invention blocks PD-L1 albumen and PD-1 by the expression of inhibition PD-L1
The combination of receptor, so that the immune function of T cell is restored in part.
Therefore, the present invention is claimed polypeptide shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3 and is inhibiting
It is applied in cell PD-L1 expression, especially the application in the cell PD-L1 expression for inhibiting IFN-γ induction；Or blocking PD-
Application in 1/PD-L1 interaction.
Meanwhile following application is also in the scope of the present invention:
Polypeptide shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3 inhibits cell PD-L1 to express medicine in preparation
It is applied in object.
Polypeptide shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3 blocks PD-1/PD-L1 mutual in preparation
Application in the drug of effect.
Application of the polypeptide in immunization therapy shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3.
Polypeptide shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3 is preparing answering in immunotherapy medicaments
With.
Polypeptide application in preparation of anti-tumor drugs shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3；
Specifically, the tumour is non-small cell lung cancer, melanoma, clear-cell carcinoma, prostate cancer, breast cancer or brain glioma
Deng.
The present invention is also claimed in 22 amino acid sequence ranges of SEQ ID NO.1 sequence, and shorter than SEQ ID
The amino acid sequence of NO.1, the polypeptide of fusion Tat or iRGD sequence, the application in immunization therapy.
In 22 amino acid sequence ranges of SEQ ID NO.1 sequence, and the amino acid sequence of shorter than SEQ ID NO.1
Column, the polypeptide of fusion Tat or iRGD sequence are preparing the application in immunotherapy medicaments.
Compared with prior art, the invention has the following advantages:
The present invention provides a kind of polypeptide of inhibition cell PD-L1 expression, amino acid sequence such as SEQ ID NO.1, SEQ
Shown in ID NO.2 or SEQ ID NO.3；Cell experiment is the results show that the cell PD-L1 that the polypeptide can inhibit IFN-γ to induce
The up-regulation of transcriptional level and protein level shows that polypeptide of the invention inhibits cell PD-L1 transcription and protein expression in preparation
Drug, and there is biggish application prospect in the drug that preparation blocks PD-1/PD-L1 interaction, it is current to be expected to substitution
The fused polypeptide of PD-L1 immunization therapy monoclonal antibody.
Detailed description of the invention
Fig. 1 is the tumour cell PD-L1 transcriptional level up-regulation that Tat-2142 fused polypeptide inhibits IFN-γ induction.
Fig. 2 is the tumour cell PD-L1 protein level up-regulation that Tat-2142 fused polypeptide inhibits IFN-γ induction.
Specific embodiment
With reference to the accompanying drawings of the specification and specific embodiment is made the present invention and is further elaborated, the implementation
Example is served only for explaining the present invention, is not intended to limit the scope of the present invention.Test method as used in the following examples for example without
Specified otherwise is conventional method；Used material, reagent etc., unless otherwise specified, for the examination commercially obtained
Agent and material.
Embodiment 1Tat-2142 fused polypeptide inhibits the tumour cell PD-L1 transcriptional upregulation of IFN-γ induction
One, method
1, the synthesis of fused polypeptide
The fused polypeptide is the synthesis of gill biochemistry Co., Ltd, the fused polypeptide sequence: YGRKKRRQRRRGGG
IPGLIWINKEEMIFQIPWKHAA, by three glycine of N-terminal by selectively targeted sequence SEQ ID NO.1 and Tat (sequence
Column: YGRKKRRQRRR) polypeptide sequence is coupled.After coupling, selectively targeted sequence SEQ ID NO.1 can be in cell-penetrating peptide
Across cell membrane under the guidance of Tat polypeptide, into cell.Meanwhile upsetting selectively targeted sequence SEQ ID NO.1 at random, then
It is coupled by the way that three glycine of N-terminal are logical with cell penetrating peptide Tat polypeptide, obtains rondom polypeptide.
2, fused polypeptide handles tumour cell
(1) A375 tumour cell is inoculated in 12 orifice plates with 30% density, 37 DEG C are pasted for cell incubator culture 24 hours
Wall.
(2) sterile PBS dissolves the fused polypeptide and rondom polypeptide dry powder of synthesis, stock concentrations 5mM respectively.
(3) above-mentioned fused polypeptide and rondom polypeptide solution are separately added into cell culture supernatant, gently shake culture plate
It mixes, final concentration of 10 μM.
(4) after being added polypeptide 4 hours, 100U/ml IFN-γ is added in cell culture supernatant, after 2,4,6 hours respectively
Orifice plate is taken out, RNA is mentioned.
3, RNA extracts kit (TIANGEN is pressed；DP430) specification operates, and extracts tumour cell RNA.
4, Reverse Transcriptase kit (Vazyme is pressed；R123-01) specification operates, by tumour cell RNA reverse transcription at cDNA.
Method and system are as follows:
Step 1: removal genomic DNA, reaction system are as follows:
1 μ g of A375 cell RNA
4×gDNA wiper Mix 4μL
Mend RNase free ddH2O to system total volume be 16 μ L.
It is uniformly mixed.
42 DEG C are incubated for 2 minutes.
Step 2: RNA reverse transcription is cDNA:
4 μ L 5 × qRTSuperMix II are added in upper step reaction system, are uniformly mixed, it is inverse by following RT-PCR program
Transcription:
50 DEG C 15 minutes
85 DEG C 2 minutes
After reaction by 10 times of cDNA product dilution, -80 DEG C save or directly carry out next step qPCR detection.
5, qPCR detects the transcriptional level of PD-L1 and internal reference GAPDH
(1) human PD-L 1 qPCR primer:
Upstream primer F:GCTGCACTAATTGTCTATTGGGA (SEQ ID NO.4)
Downstream primer R:AATTCGCTTGTAGTCGGCACC (SEQ ID NO.5)
People's GAPDH qPCR primer:
Upstream primer F:TGACTTCAACAGCGACACCC (SEQ ID NO.6)
Downstream primer R:CTGGTGGTCCAGGGGTCTTA (SEQ ID NO.7)
(2) it according to following reaction system and program, is detected with Roche fluorescence quantitative PCR instrument；
QPCR reaction system:
QPCR response procedures:
Two, testing result
Experimental result is as shown in Figure 1, in the stimulation of no interferon, rondom polypeptide group and processing group PD-L1
MRNA level in-site does not have difference, and illustrating Tat-2142 fused polypeptide not influences A375 cell PD-L1 mRNA expression；In interferon
Under stimulation, rondom polypeptide group increases with stimulation time, and PD-L1 mRNA level in-site significantly increases, and processing group PD-L1 mRNA water
Flat elevation amplitude is smaller, and substantially less than rondom polypeptide group.The result shows that Tat-2142 fused polypeptide can significantly inhibit IFN-γ
The tumour cell PD-L1 transcriptional upregulation of induction.
Embodiment 2Tat-2142 fused polypeptide inhibits the tumour cell PD-L1 protein upregulation of IFN-γ induction
One, method
1, the synthesis of fused polypeptide
The fused polypeptide is the synthesis of gill biochemistry Co., Ltd, the fused polypeptide sequence: YGRKKRRQRRRGGG
IPGLIWINKEEMIFQIPWKHAA, by three glycine of N-terminal by selectively targeted sequence SEQ ID NO.1 and Tat (sequence
Column: YGRKKRRQRRR) polypeptide sequence is coupled.After coupling, selectively targeted sequence SEQ ID NO.1 can be in cell-penetrating peptide
Across cell membrane under the guidance of Tat polypeptide, into cell.Meanwhile upsetting selectively targeted sequence SEQ ID NO.1 at random, then
It is coupled by the way that three glycine of N-terminal are logical with cell penetrating peptide Tat polypeptide, obtains rondom polypeptide.
2, fused polypeptide handles tumour cell
(1) A375 tumour cell is inoculated in 12 orifice plates with 30% density, 37 cell incubator cultures 24 hours are adherent.
(2) sterile PBS dissolves the fused polypeptide and rondom polypeptide dry powder of synthesis, stock concentrations 5mM respectively.
(3) above-mentioned fused polypeptide and rondom polypeptide solution are separately added into cell culture supernatant, gently shake culture plate
It mixes, final concentration of 10 μM.
(4) after being added polypeptide 4 hours, 100U/ml IFN-γ is added in cell culture supernatant, sets in cell incubator
Culture took out orifice plate, lytic cell leach protein after 2,4,6 hours respectively.
3, albumen is extracted
(1) orifice plate is taken out from cell incubator, removes supernatant, after washing twice of cell with ice-cold PBS, be placed on ice.
(2) the ice-cold RIPA that 100 μ L contain protease and inhibitors of phosphatases is added in every hole, and shaking gently orifice plate makes RIPA
Cover whole surface.15min is cracked on ice.
(3) albumen is scraped, is collected in 1.5ml EP pipe, 12000rpm 4 is centrifuged 10min
(4) supernatant is transferred in new EP pipe, the loading buffer containing 4%SDS and DTT is added, mixed.
(5) 100 metal bath 5min
(6) short from the centrifugation of droplet that pipe covers down.
(7) -20 save albumen or direct loading Western Blot detection.
Two, testing result
Experimental result is as shown in Fig. 2, in the stimulation of no interferon, rondom polypeptide group and processing group PD-L1 egg
White level does not have difference, and illustrating Tat-2142 fused polypeptide not influences A375 cell PD-L1 protein expression；It is stimulated in interferon
Under, rondom polypeptide group increases with stimulation time, and PD-L1 protein level significantly increases, and processing group PD-L1 protein level increases
Amplitude is smaller, and substantially less than rondom polypeptide group.The result shows that Tat-2142 fused polypeptide can significantly inhibit IFN-γ induction
Tumour cell PD-L1 protein upregulation.
Embodiment 3
According to the synthetic method of embodiment 1, targeted fusion polypeptide 2142-iRGD:IPGLIWINKEEM as described below is synthesized
IFQIPWKHAAGGGCRGDKGPDC(SEQ ID NO.3)；The fused polypeptide sequence by two cysteines of its C-terminal at
Selectively targeted sequence SEQ ID NO.1 and iRGD cancer target polypeptide sequence are coupled by ring particular by three glycine
It forms, can preferably play the targeted therapy effect of polypeptide described in SEQ ID NO.1.Meanwhile according to described in Examples 1 and 2
Method handles tumour cell with targeted fusion polypeptide 2142-iRGD, the results show that targeted fusion polypeptide 2142-iRG can be significant
The up-regulation of cell PD-L1 transcriptional level and protein level that IFN-γ can be inhibited to induce blocks PD-1/PD-L1 interaction, and
Tumour-specific is also had in animal body.
Claims (10)
1. a kind of polypeptide for inhibiting PD-L1 expression, which is characterized in that the amino acid sequence of the polypeptide such as SEQ ID NO.1 institute
Show.
2. a kind of Tat-2142 fused polypeptide for inhibiting PD-L1 expression, which is characterized in that the amino acid sequence of the polypeptide is such as
Shown in SEQ ID NO.2.
3. a kind of 2142-iRGD fused polypeptide for inhibiting PD-L1 expression, which is characterized in that the amino acid sequence of the fused polypeptide
Column are as shown in SEQ ID NO.3.
4. fused polypeptide according to claim 3, which is characterized in that the iRGD polypeptide sequence passes through its end amino acid
Cyclization.
5. claim 1,2 or 3 polypeptides are inhibiting cell PD-L1 expression, or in blocking PD-1/PD-L1 interaction
Application.
6. applying according to claim 5, which is characterized in that the inhibition cell PD-L1 expression is to inhibit cell PD-L1
The expression of transcription and albumen.
7. claim 1,2 or 3 polypeptides are applied in the drug that preparation inhibits cell PD-L1 expression.
8. the application of claim 1,2 or 3 polypeptides in the drug that preparation blocks PD-1/PD-L1 interaction.
9. claim 1,2 or the 3 polypeptide application in preparations of anti-tumor drugs.
10. a kind of inhibition cell PD-L1 expresses drug, which is characterized in that the drug contains SEQ ID NO.1, SEQ ID
Polypeptide shown in NO.2 or SEQ ID NO.3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910185978.2A CN110054666B (en) | 2019-03-12 | 2019-03-12 | Polypeptide for inhibiting expression of cell PD-L1 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910185978.2A CN110054666B (en) | 2019-03-12 | 2019-03-12 | Polypeptide for inhibiting expression of cell PD-L1 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110054666A true CN110054666A (en) | 2019-07-26 |
| CN110054666B CN110054666B (en) | 2021-01-01 |
Family
ID=67316795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910185978.2A Active CN110054666B (en) | 2019-03-12 | 2019-03-12 | Polypeptide for inhibiting expression of cell PD-L1 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110054666B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111393509A (en) * | 2020-03-30 | 2020-07-10 | 国家纳米科学中心 | Target specific polypeptide and application thereof |
| CN114671926A (en) * | 2022-04-07 | 2022-06-28 | 江苏大学 | Amphipathic alpha-helical polypeptide for inhibiting PD-L1 and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017072280A1 (en) * | 2015-10-30 | 2017-05-04 | Affibody Ab | New polypeptide having affinity to pd-l1 |
| CN108840923A (en) * | 2018-06-22 | 2018-11-20 | 上海交通大学医学院附属仁济医院 | It is a kind of target PD-L1 polypeptide and its application |
-
2019
- 2019-03-12 CN CN201910185978.2A patent/CN110054666B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017072280A1 (en) * | 2015-10-30 | 2017-05-04 | Affibody Ab | New polypeptide having affinity to pd-l1 |
| CN108840923A (en) * | 2018-06-22 | 2018-11-20 | 上海交通大学医学院附属仁济医院 | It is a kind of target PD-L1 polypeptide and its application |
Non-Patent Citations (2)
| Title |
|---|
| ZHENLIANG SUN等: "PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer", 《DRUG DELIBERY》 * |
| 刘笑等: "程序性死亡受体-1/程序性死亡受体-配体1信号通路小分子抑制剂的研究进展", 《药学进展》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111393509A (en) * | 2020-03-30 | 2020-07-10 | 国家纳米科学中心 | Target specific polypeptide and application thereof |
| CN111393509B (en) * | 2020-03-30 | 2022-03-29 | 国家纳米科学中心 | Target specific polypeptide and application thereof |
| CN114671926A (en) * | 2022-04-07 | 2022-06-28 | 江苏大学 | Amphipathic alpha-helical polypeptide for inhibiting PD-L1 and application thereof |
| CN114671926B (en) * | 2022-04-07 | 2024-03-19 | 江苏大学 | Amphipathic alpha-helical polypeptide for inhibiting PD-L1 and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110054666B (en) | 2021-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hou et al. | Navigating CAR-T cells through the solid-tumour microenvironment | |
| Huyghe et al. | Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? | |
| Choi et al. | Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine Kras mutant lung cancer | |
| Zhou et al. | Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras | |
| TWI558411B (en) | FOXM1 peptides and agents containing this peptide | |
| CN106749675A (en) | A kind of recombinant slow virus and its application | |
| Li et al. | Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model | |
| Yang et al. | Progresses and perspectives of anti-PD-1/PD-L1 antibody therapy in head and neck cancers | |
| CN104356225B (en) | CDH3 peptides and the medicament containing CDH3 peptides | |
| CN102482354A (en) | Anti ceacam1 antibodies and methods of using same | |
| CN105579058A (en) | Medical uses of cd38 agonists | |
| CN104114233A (en) | Switch co-stimulatory receptors | |
| CN108085340A (en) | A kind of slow virus carrier of CAR and PD1-CD28 Chimerical receptor that is while expressing targeting CD19 and CD20 | |
| CN107488636A (en) | A kind of immunocyte of anti-HER2 Chimeric antigen receptors modification for carrying molecular switch and its application | |
| Meghnani et al. | The receptor for advanced glycation end products influences the expression of its S100 protein ligands in melanoma tumors | |
| CN108300699A (en) | NK cells of modification and application thereof | |
| CN114286681A (en) | Use of NAD + and/or NAD + inhibitors and/or NAD + agonists and combined preparations thereof | |
| Panagi et al. | Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness | |
| CN110054666A (en) | A kind of polypeptide and its application for inhibiting cell PD-L1 to express | |
| CN109593726A (en) | Enhancing CAR-T cell is gone back to the nest reagent and its application to solid tumor tissue ability | |
| Aquino et al. | Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. | |
| CN114835781B (en) | WTN polypeptide and application thereof in detection and treatment of cancer | |
| EP3552618B1 (en) | Transgrelin-2 for treating cancer and improving cytotoxic acitivity of the cancer killer cell | |
| CN102348796B (en) | Novel cancer antigen eEF2 | |
| Yamanouchi et al. | The Wilms' tumor gene WT1− 17AA/− KTS splice variant increases tumorigenic activity through up-regulation of vascular endothelial growth factor in an in vivo ovarian cancer model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |